Evonik Launches EUDRACAP Colon Functional Capsules for the Targeted Delivery of Oral Drugs
Evonik is expanding its EUDRACAP portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP colon has been designed to meet the high customer need for a capsule that can deliver sensitive active ingredients, such as live biotherapeutic products (LBPs) to treat or prevent a wide range of diseases, to the ileo-colonic region. It is currently available in technical grade with a GMP-grade product in development. EUDRACAP functional capsules help streamline the development of oral drugs, reducing complexity in formulation and increasing speed to market.
Evonik’s EUDRACAP platform leverages EUDRAGIT coatings for tailored oral drug release. For 70 years, Evonik has been providing EUDRAGIT polymers as key ingredients in system solutions. These multi-component systems are tailored to unique and specific customer needs and through continuous innovation are driving a transformation to system solutions within Evonik’s life sciences division, Nutrition & Care.
“Drawing on decades of know-how, we are working with customers on new paths for ileo-colonic delivery. Our EUDRACAP platform is a testament to strong innovation and growth and we are delighted to expand this portfolio,” said Axel Schroeder, Head of Oral Drug Delivery Solutions at Evonik.
EUDRACAP colon can be used for the delivery of sensitive active ingredients such as live biotherapeutics, oral biologics, proteins, peptides and nucleotides (RNA). These actives are used in the formulation of innovative drugs for the treatment of severe conditions such as obesity, HIV, or Cystic Fibrosis, as well as for local delivery such as for colorectal cancer and infections.
EUDRACAP colon is the latest addition to Evonik’s EUDRACAP platform of innovations for oral drug delivery. In 2021, the company launched EUDRACAP enteric to optimize gastric resistance, boost intestinal absorption and enhance bioavailability. Together with the EUDRACAP Select line, Evonik provides tailor-made CDMO (Contract Development and Manufacturing Organization) services for customer requirements including a range of sizes, colors, and customized release profiles. In 2023, Evonik launched EUDRACAP preclinic, for preclinical trials.
Over 7 decades, EUDRAGIT methacrylate polymers have established themselves as the industry standard with more than 23,000 patents and 10,000 scientific publications mentioning the EUDRAGIT brand. Today, customers in over 80 countries use EUDRAGIT polymers in their formulations for modified release.
Evonik Health Care has been a leader in advanced drug delivery for decades, supporting pharmaceutical companies worldwide with comprehensive services for the development of complex oral and parenteral drug products. This includes pharmaceutical excipients, formulation development and the manufacture of clinical samples, as well as commercial drug products. Furthermore, the business serves as a CDMO for APIs and intermediates and has a strong focus on growth fields such as lipid-based mRNA and gene delivery, and cell culture solutions for biopharma applications. For more information, visit EUDRACAP® portfolio.
Total Page Views: 368
